Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967184 | 0.95 | MMP8 (0.49) | MMP8KMT2AALDH1A1RECQLNAAA | |
| SCHEMBL1963392 | 0.89 | MMP8 (0.47) | MMP8KMT2AALDH1A1RECQLNAAA | |
| SCHEMBL2220152 | 0.86 | MAPT (0.45) | MAPTRAB9A | |
| SCHEMBL20390925 | 0.80 | MMP8 (0.55) | MMP8KMT2AALDH1A1RECQLMAPT | |
| SCHEMBL11864228 | 0.80 | MMP8 (0.55) | MMP8KMT2AALDH1A1RECQLMAPT | |
| SCHEMBL12437325 | 0.80 | MMP8 (0.37) | MMP8KMT2A | |
| Hydrochloric Acid SCHEMBL11864224 | 0.79 | MMP8 (0.54) | MMP8KMT2AALDH1A1RECQLMAPT | |
| SCHEMBL3125403 | 0.78 | IDO1 (0.47) | — | |
| SCHEMBL2217368 | 0.77 | KMT2A (0.42) | MMP8KMT2AMAPTRAB9AMEN1 | |
| SCHEMBL2223083 | 0.77 | MAPT (0.47) | MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HCAR1, H1-0, HDAC1 | MMP8 544/4885KMT2A 708/4885ALDH1A1 272/4885 |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | HCAR1, HDAC1, H1-0 | MMP8 564/4885KMT2A 681/4885ALDH1A1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.